Skip to content

Value of micro-proteinuria in combination with ultrasonography of the left renal vein in the diagnosis of orthostatic proteinuria

Value of micro-proteinuria in combination with ultrasonography of the left renal vein in the diagnosis of orthostatic proteinuria

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035953
Enrollment
Unknown
Registered
2020-08-20
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthostatic proteinuria

Interventions

Gold Standard:All of West test, Upright lordotic posture test and Robinson test are positive.
Index test:Micro-proteinuria&#32
and&#32
of&#32
the&#32

Sponsors

Shanghai Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: OP group: 1. Proteinuria of the morning urine is negative. 24-hour proteinuria0.15g. 3. All of West test, Upright lordotic posture test and Robinson test are negative.

Exclusion criteria

Exclusion criteria: OP group: The patients with other primary and secondary kidney diseases or anyone of West test, Upright lordotic posture test and Robinson test is negative are excluded. Negative control group: The patients with other primary and secondary kidney diseases or anyone of West test, Upright lordotic posture test and Robinson test is positive are excluded. Pathological proteinuria group:The patients with anyone of West test, Upright lordotic posture test and Robinson test is positive are excluded.

Design outcomes

Primary

MeasureTime frame
Micro-proteinuria;Proteinuria;ultrasonography of the left renal vein;

Secondary

MeasureTime frame
24-hour proteinuria;

Countries

China

Contacts

Public ContactXiao-Ling Niu

Shanghai Children's Hospital

niuxl@shchildren.com.cn+86 13764121599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026